Sensitivity of NS3 Serine Proteases from Hepatitis C Virus Genotypes 2 and 3 to the Inhibitor BILN 2061
- 15 July 2004
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 78 (14) , 7352-7359
- https://doi.org/10.1128/jvi.78.14.7352-7359.2004
Abstract
Hepatitis C virus (HCV) displays a high degree of genetic variability. Six genotypes and more than 50 subtypes have been identified to date. In this report, kinetic profiles were determined for NS3 proteases of genotypes 1a, 1b, 2ac, 2b, and 3a, revealing no major differences in activity. In vitro sensitivity studies with BILN 2061 showed a decrease in affinity for proteases of genotypes 2 and 3 (Ki, 80 to 90 nM) compared to genotype 1 enzymes (Ki, 1.5 nM). To understand the reduced sensitivity of genotypes 2 and 3 to BILN 2061, active-site residues in the proximity of the inhibitor binding site were replaced in the genotype-1b enzyme with the corresponding genotype-2b or -3a residues. The replacement of five residues at positions 78, 79, 80, 122, and 132 accounted for most of the reduced sensitivity of genotype 2b, while replacement of residue 168 alone could account for the reduced sensitivity of genotype 3a. BILN 2061 remains a potent inhibitor of these non-genotype-1 NS3-NS4A proteins, withKivalues below 100 nM. This in vitro potency, in conjunction with the good pharmacokinetic data reported for humans, suggests that there is potential for BILN 2061 as an antiviral agent for individuals infected with non-genotype-1 HCV.Keywords
This publication has 37 references indexed in Scilit:
- An NS3 Serine Protease Inhibitor Abrogates Replication of Subgenomic Hepatitis C Virus RNAJournal of Biological Chemistry, 2003
- Macrocyclic Inhibitors of the NS3 Protease as Potential Therapeutic Agents of Hepatitis C Virus InfectionAngewandte Chemie International Edition in English, 2003
- In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide InhibitorJournal of Virology, 2003
- A Major Role for a Set of Non-Active Site Mutations in the Development of HIV-1 Protease Drug ResistanceBiochemistry, 2003
- Course and outcome of hepatitis CHepatology, 2002
- Optimal therapy of hepatitis CHepatology, 2002
- Emergence and selection of RNA virus variants: memory and extinctionVirus Research, 2001
- HCV genotypes—role in pathogenesis of disease and response to therapyBest Practice & Research Clinical Gastroenterology, 2000
- Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α TherapyScience, 1998
- Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: A 2.2 Å resolution structure in a hexagonal crystal formProtein Science, 1998